<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>To evaluate the efficacy and safety of subcutaneous administration of recombinant human granulocyte colony-stimulating factor (rhG-CSF) in <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (AA), 21 patients were given a daily subcutaneous dose of 200 micrograms/m2 of KRN8601 for 4 weeks </plain></SENT>
<SENT sid="1" pm="."><plain>When the blood neutrophil count did not reach 2,000/microliters within 2 weeks, the dose was increased to 400 micrograms/m2 </plain></SENT>
<SENT sid="2" pm="."><plain>A marked neutrophilic response was obtained in <z:hpo ids='HP_0000001'>all</z:hpo> 9 patients with non-severe AA and in 9 out of the 12 patients with severe AA, yielding a response rate of 85.7% </plain></SENT>
<SENT sid="3" pm="."><plain>Adverse effects included lumbago in one patient and elevation of serum enzyme levels in 6 patients, but did not prohibit further treatment </plain></SENT>
<SENT sid="4" pm="."><plain>These results suggest that subcutaneous administration of KRN8601 is safe and useful in improving <z:hpo ids='HP_0001875'>neutropenia</z:hpo> in AA </plain></SENT>
</text></document>